X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-18 | CTMX | McCarthy Sean A. | CEO | S - Sale | $0.60 | -37,656 | 1,088,353 | -3% | -$22,556 | ||||||
2025-03-18 | CTMX | Ogden Christopher | CFO | S - Sale | $0.60 | -8,551 | 201,026 | -4% | -$5,122 | ||||||
2025-03-18 | CTMX | Chu Yu-Waye | Chief Medical Officer | S - Sale | $0.60 | -4,025 | 135,725 | -3% | -$2,411 | ||||||
2025-03-18 | CTMX | Rowland Lloyd A | GC | S - Sale | $0.60 | -10,203 | 120,594 | -8% | -$6,112 | ||||||
2025-03-18 | CTMX | Belvin Marcia | SVP, Chief Scientific Officer | S - Sale | $0.60 | -19,512 | 248,636 | -7% | -$11,688 | ||||||
| D | 2024-08-20 | CTMX | Landau Jeffrey B | Chief Business Officer | S - Sale+OE | $1.23 | -4,181 | 126,736 | -3% | -$5,139 | |||||
| D | 2024-08-20 | CTMX | Belvin Marcia | SVP, Chief Scientific Officer | S - Sale+OE | $1.23 | -4,181 | 175,648 | -2% | -$5,139 | |||||
| D | 2024-08-20 | CTMX | Rowland Lloyd A | GC | S - Sale+OE | $1.23 | -4,181 | 130,797 | -3% | -$5,139 | |||||
| D | 2024-08-20 | CTMX | Ogden Christopher | CFO | S - Sale+OE | $1.23 | -1,984 | 108,077 | -2% | -$2,439 | |||||
| D | 2024-08-20 | CTMX | McCarthy Sean A. | CEO | S - Sale+OE | $1.23 | -13,898 | 751,009 | -2% | -$17,082 | |||||
2024-03-19 | CTMX | Rowland Lloyd A | GC | S - Sale | $2.09 | -5,268 | 117,728 | -4% | -$10,986 | ||||||
2024-03-19 | CTMX | McCarthy Sean A. | CEO | S - Sale | $2.09 | -20,223 | 617,639 | -3% | -$42,175 | ||||||
2024-03-19 | CTMX | Ogden Christopher | SVP, Finance, Accounting | S - Sale | $2.09 | -2,971 | 85,686 | -3% | -$6,196 | ||||||
2024-03-19 | CTMX | Belvin Marcia | SVP, Chief Scientific Officer | S - Sale | $2.09 | -12,795 | 168,579 | -7% | -$26,684 | ||||||
2024-03-19 | CTMX | Landau Jeffrey B | Chief Business Officer | S - Sale | $2.09 | -6,562 | 117,740 | -5% | -$13,685 | ||||||
2023-12-20 | CTMX | McCarthy Sean A. | CEO | S - Sale | $1.38 | -13,551 | 547,862 | -2% | -$18,710 | ||||||
2023-12-20 | CTMX | Belvin Marcia | SVP, Chief Scientific Officer | S - Sale | $1.38 | -4,077 | 155,124 | -3% | -$5,628 | ||||||
2023-12-20 | CTMX | Landau Jeffrey B | Chief Business Officer | S - Sale | $1.38 | -4,077 | 94,302 | -4% | -$5,628 | ||||||
2023-12-20 | CTMX | Rowland Lloyd A | GC | S - Sale | $1.38 | -4,077 | 97,996 | -4% | -$5,629 | ||||||
2023-12-20 | CTMX | Ogden Christopher | SVP, Finance, Accounting | S - Sale | $1.38 | -1,990 | 48,657 | -4% | -$2,747 | ||||||
2023-09-22 | CTMX | Belvin Marcia | SVP, Chief Scientific Officer | S - Sale | $1.30 | -4,119 | 147,951 | -3% | -$5,356 | ||||||
2023-09-22 | CTMX | Landau Jeffrey B | Chief Business Officer | S - Sale | $1.30 | -4,119 | 84,059 | -5% | -$5,356 | ||||||
2023-09-22 | CTMX | McCarthy Sean A. | CEO | S - Sale | $1.30 | -14,601 | 523,913 | -3% | -$18,987 | ||||||
2023-09-22 | CTMX | Rowland Lloyd A | GC | S - Sale | $1.30 | -5,486 | 80,609 | -6% | -$7,135 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |